DNA Sequencing Tests Identify Causes of Infections in Immunocompromised Patients with Alec Ford Karius

Alec Ford, CEO of Karius, has developed an innovative approach to diagnosing infections in immunocompromised patients, using DNA sequencing of blood samples to identify over 1,300 causes of infection within 24 hours. Traditional diagnostic methods rely on hypothesis-driven testing and the cultivation of organisms. At the same time, the Karius approach enables faster, more targeted antibiotic treatment, reduces unnecessary broad-spectrum antibiotics, and can identify infections that may not be included in the initial diagnosis. Time to proper treatment is essential for vulnerable populations, including cancer patients, HIV-positive individuals, organ transplant recipients, and those undergoing autoimmune therapies.  Alec explains, "These are patients going through cancer treatment, patients with HIV, people going through solid organ transplantation, or people being treated assertively with autoimmune therapies for autoimmune disorders, where it may compromise their immune system. That really vulnerable patient is our exclusive focus as a company."   "So, a patient gets admitted to the hospital for an infection. They take a sample of that patient's blood. And what we can do is diagnose over 1,300 causes of infection by sequencing the patient's blood for viruses, parasites, bacteria, and fungi that could threaten the success of their cancer treatment or solid organ transplant. There's never been a test in the history of infectious disease that can test for any DNA-based organism, and we do so. We can return a result 24 hours after we receive the sample."   #Karius #InfectiousDisease #Diagnostics #Metagenomics #MedTech #KariusSpectrum #KariusFocus #NextGenSequencing #ImmunocompromisedCare #Oncology #TransplantMedicine #AntimicrobialStewardship #Genomics #MolecularDiagnostics #KariusTest #PatientSafety #HealthcareInnovation Kariusdx.com  Download the transcript here